Holen Sie sich die Stockscreener-App
1.90
0.52%
-0.01
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
Bank license renewal backs BIO-key (NASDAQ: BKYI) biometric growth - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
Adicet Bio Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio furnishes corporate presentation detailing CORDStrom and XPro1595 development plans - TradingView
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
TRML SEC FilingsTourmaline Bio 10-K, 10-Q, 8-K Forms - Stock Titan
TELA SEC FilingsTela Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
[SCHEDULE 13G/A] GRI Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
BioXcel (NASDAQ: BTAI) updates IGALMI at-home treatment opportunity - Stock Titan
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Severe asthma trial: experimental drug cuts attacks up to 56% - Stock Titan
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation - Stock Titan
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - The Manila Times
What’s the outlook for Third Harmonic Bio Inc.’s sectorWeekly Trade Review & Entry Point Confirmation Alerts - mfd.ru
Rare 'butterfly skin' disease therapy takes key step toward UK review - Stock Titan
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewswire Inc.
Avant Technologies (AVAI) changes its name to Avaí Bio, Inc. - Stock Titan
KALA BIO (KALA) names director Avi Minkowitz CEO and CFO as David Lazar steps down - Stock Titan
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Biotech Climb Bio to field questions at Guggenheim, Oppenheimer, Leerink events - stocktitan.net
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend - TradingView
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):